(Q35841043)

English

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

scientific article published on 16 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib (English)

1 reference

Europe PubMed Central

10 August 2017

Mari Mino-Kenudson

15

object named as

Mari Mino-Kenudson

0 references

11

object named as

Keith T Flaherty

1 reference

Europe PubMed Central

10 August 2017

Dora Dias-Santagata

9

object named as

Dora Dias-Santagata

1 reference

Europe PubMed Central

10 August 2017

Jeffrey A Engelman

16

object named as

Jeffrey A Engelman

1 reference

Europe PubMed Central

10 August 2017

Ryan B Corcoran

1

object named as

Ryan B Corcoran

1 reference

Europe PubMed Central

10 August 2017

Jeffrey Settleman

14

object named as

Jeffrey Settleman

1 reference

Europe PubMed Central

10 August 2017

13

object named as

Jennifer A Wargo

1 reference

Europe PubMed Central

10 August 2017

12

object named as

Adriano Piris

1 reference

Europe PubMed Central

10 August 2017

author name string

Hiromichi Ebi

2

1 reference

Europe PubMed Central

10 August 2017

Alexa B Turke

3

1 reference

Europe PubMed Central

10 August 2017

Erin M Coffee

4

1 reference

Europe PubMed Central

10 August 2017

Michiya Nishino

5

1 reference

Europe PubMed Central

10 August 2017

Alexandria P Cogdill

6

1 reference

Europe PubMed Central

10 August 2017

Ronald D Brown

7

1 reference

Europe PubMed Central

10 August 2017

Patricia Della Pelle

8

1 reference

Europe PubMed Central

10 August 2017

Kenneth E Hung

10

1 reference

Europe PubMed Central

10 August 2017

publication date

16 January 2012

1 reference

Europe PubMed Central

10 August 2017

Cancer Discovery

1 reference

Europe PubMed Central

10 August 2017

2

1 reference

Europe PubMed Central

10 August 2017

227-235

1 reference

Europe PubMed Central

10 August 2017

3

1 reference

Europe PubMed Central

10 August 2017

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Intermolecular interactions of Sprouty proteins and their implications in development and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Targeting the RAF-MEK-ERK pathway in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

24 September 2018

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

24 September 2018

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

24 September 2018

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

24 September 2018

Identifiers

10.1158/2159-8290.CD-11-0341

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35841043&oldid=2119045618"